Search research articles
Contact Us
Filters
Showing results (11-20 of 36) with videos related to
Page
of 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 27, 2006
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians
Lori Kay Mattison, Jeanne Fourie, Renee A Desmond, et al.
Journal of Patient-Reported Outcomes
|
November 17, 2023
Use of patient-reported outcomes (PRO) data to complement exposure-response analysis in early clinical cancer drug development
Huiming Xia, Brian P Booth, Yaning Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2006
The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil
Lori K Mattison, Jeanne Fourie, Yukihiro Hirao, et al.
The Oncologist
|
May 8, 2026
Shifting a paradigm: highlights of model informed drug development in dosage selection and optimization for oncology products
Ye Xiong, Robyn Konicki, Jeanne Fourie Zirkelbach, et al.
The Oncologist
|
May 4, 2026
Shifting a Paradigm: Highlights of Model Informed Drug Development in Dosage Selection and Optimization for Oncology Products
Ye Xiong, Robyn Konicki, Jeanne Fourie Zirkelbach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2023
US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non-Small-Cell Lung Cancer
Oladimeji Akinboro, Nicole Drezner, Anup Amatya, et al.
Oncology
|
June 10, 2010
FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation
Michael Brave, Ann Farrell, Sue Ching Lin, et al.
The Oncologist
|
February 2, 2018
Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib
Lorraine Pelosof, Steven Lemery, Sandra Casak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2017
FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma
Amy Barone, Maitreyee Hazarika, Marc R Theoret, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 12, 2022
Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients
Jeanne Fourie Zirkelbach, Mirat Shah, Jonathon Vallejo, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 36) with videos related to
Sort By:
Page
of 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 27, 2006
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians
Lori Kay Mattison, Jeanne Fourie, Renee A Desmond, et al.
Journal of Patient-Reported Outcomes
|
November 17, 2023
Use of patient-reported outcomes (PRO) data to complement exposure-response analysis in early clinical cancer drug development
Huiming Xia, Brian P Booth, Yaning Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2006
The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil
Lori K Mattison, Jeanne Fourie, Yukihiro Hirao, et al.
The Oncologist
|
May 8, 2026
Shifting a paradigm: highlights of model informed drug development in dosage selection and optimization for oncology products
Ye Xiong, Robyn Konicki, Jeanne Fourie Zirkelbach, et al.
The Oncologist
|
May 4, 2026
Shifting a Paradigm: Highlights of Model Informed Drug Development in Dosage Selection and Optimization for Oncology Products
Ye Xiong, Robyn Konicki, Jeanne Fourie Zirkelbach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2023
US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non-Small-Cell Lung Cancer
Oladimeji Akinboro, Nicole Drezner, Anup Amatya, et al.
Oncology
|
June 10, 2010
FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation
Michael Brave, Ann Farrell, Sue Ching Lin, et al.
The Oncologist
|
February 2, 2018
Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib
Lorraine Pelosof, Steven Lemery, Sandra Casak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2017
FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma
Amy Barone, Maitreyee Hazarika, Marc R Theoret, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 12, 2022
Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients
Jeanne Fourie Zirkelbach, Mirat Shah, Jonathon Vallejo, et al.
Page
of 4